Detailed explanation of the current status and scope of application of platinib medical insurance in 2024

Pralsetinib (Pralsetinib), known by the trade name Gavreto, is an oral, once-daily, potent and highly selective RET inhibitor developed by Blueprint Medicines. This drug has demonstrated significant therapeutic efficacy in the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are positive for transfection rearrangement (RET) gene fusions, as well as adults and children aged 12 years and older with advanced or metastatic RET-mutated medullary thyroid cancer (MTC). At the same time, it also provides a new treatment option for adults and pediatric patients 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer that requires systemic therapy and is refractory to radioactive iodine. By precisely inhibiting the phosphorylation of RET and its downstream molecules, Platinib effectively blocks the proliferation of cells expressing RET gene mutations, thereby curbing the growth and spread of tumors.

However, as of 2024, Platinib has not yet been officially included in my country’s medical insurance coverage. This means that patients need to bear all costs when purchasing and using the drug. This undoubtedly places a considerable burden on many patients, especially those with greater financial pressure. In order to reduce financial pressure, some patients may consider choosing the generic version of Platinib launched by Lucius Pharmaceuticals in Laos. The specification of this generic medicine is 100mg*120 tablets, and the price of a box is about 4,000 to 5,000 yuan. Compared with the original medicine, it is more cost-effective. However, patients must be cautious when choosing to purchase medicines overseas. They should choose overseas medical institutions with good reputation and formal cooperative relations with pharmaceutical companies, or go to Laos Lucius Pharmaceutical Factory to purchase in person to ensure the authenticity and quality of the medicines purchased.

As a prescription drug, Platinib must be used strictly in accordance with medical instructions. Before receiving treatment, patients should consult a professional doctor in detail to fully understand the usage, dosage, possible side effects and other precautions of the drug. Only in this way can the safety and effectiveness of treatment be ensured.

Although platinib is not currently covered by medical insurance, it brings new treatment hope to many patients withRET gene fusion-positive non-small cell lung cancer and thyroid cancer. With the continuous improvement and progress of medical policies, we have reason to believe that platinib is expected to be included in the scope of medical insurance in the future, thus providing financial support and protection to more patients. Prior to this, patients and family members should actively understand relevant policies and information and plan treatment plans appropriately.